• 한국임상수의학회지
• /
• 제20권2호
• /
• pp.224-228
• /
• 2003

This study was performed to evaluate the effect of electroacupuncture at some acupoint combinations on the cardiovascular system, especially on blood pressure. Electroacupuncture at acupoint combinations of CV2O(+)/GV-16(-),4(+)/GV16(-), KI1(+)/GV20(-), and HT9(+)/GV16(-) did not changed heart rates and blood pressure, but stimulation of HT1(+)/HT7(-) Increased systolic, diastolic and mean arterial blood pressure significantly in dogs anesthetized with tiletamine/zolazepam.

• The Korean Journal of Physiology and Pharmacology
• /
• 제20권4호
• /
• pp.407-414
• /
• 2016

This study was performed to investigate whether the spinal cholinergic and serotonergic analgesic systems mediate the relieving effect of electroacupuncture (EA) on oxaliplatin-induced neuropathic cold allodynia in rats. The cold allodynia induced by an oxaliplatin injection (6 mg/kg, i.p.) was evaluated by immersing the rat's tail into cold water ($4^{\circ}C$) and measuring the withdrawal latency. EA stimulation (2 Hz, 0.3-ms pulse duration, 0.2~0.3 mA) at the acupoint ST36, GV3, or LI11 all showed a significant anti-allodynic effect, which was stronger at ST36. The analgesic effect of EA at ST36 was blocked by intraperitoneal injection of muscarinic acetylcholine receptor antagonist (atropine, 1 mg/kg), but not by nicotinic (mecamylamine, 2 mg/kg) receptor antagonist. Furthermore, intrathecal administration of $M_2$ (methoctramine, $10{\mu}g$) and $M_3$ (4-DAMP, $10{\mu}g$) receptor antagonist, but not $M_1$ (pirenzepine, $10{\mu}g$) receptor antagonist, blocked the effect. Also, spinal administration of $5-HT_3$ (MDL-72222, $12{\mu}g$) receptor antagonist, but not $5-HT_{1A}$ (NAN-190, $15{\mu}g$) or $5-HT_{2A}$ (ketanserin, $30{\mu}g$) receptor antagonist, prevented the anti-allodynic effect of EA. These results suggest that EA may have a significant analgesic action against oxaliplatin-induced neuropathic pain, which is mediated by spinal cholinergic ($M_2$, $M_3$) and serotonergic ($5-HT_3$) receptors.